Buy Xebec for exposure to renewable energy space, Paradigm Capital says

Paradigm Capital’s Jason Tucker has launched coverage of cleantech company Xebec Adsorption (Xebec Adsorption Stock Quote, Chart TSX:XBC) with a “Buy” rating and 12-month target of $2.00, representing a projected return of 38 per cent at the time of publication.

In a coverage initiation on Monday, Tucker states that Xebec, which makes equipment and technology to transform gases into marketable sources of energy, was ahead of the curve when in 2009 it combined businesses with gas purification company QuestAir.

“Renewable Natural Gas (RNG) was a huge opportunity but the company was having trouble capturing attention,” says Tucker. “Xebec saw what was unfolding in the German market but was years ahead of other governments and industry.”

“However, the rest of the world is finally catching up. The market for RNG is growing exponentially and Xebec is at the forefront with its offerings to address this growing demand. The company’s backlog reflects the recent surge in activity and shift in mindset,” he says.

The analyst notes that Xebec’s clean technology segment now has an order backlog of about $71 million, up from $10.6 million at the end of 2017, with a current sales activity pipeline of over $500 million. He underlines that the company has roughly nine per cent of the Canadian market for adsorption systems but hopes to be capturing 30 to 40 per cent by 2020, with EBITDA margins in the range of 17 to 20 per cent and $10 to $12 million in recurring revenue from this segment.

“Xebec represents an opportunity for investors to gain exposure to the renewable energy space via a small but growing entity. The company’s performance record with over 200 gas installations globally and ~$60 million of investments in proprietary technology give us every confidence Xebec will emerge as a leader in the growing market for RNG,” says Tucker.

The analyst predicts that XBC will generate fiscal 2019 revenue and EBITDA of $53 million and $5.9 million, respectively, and fiscal 2020 revenue and EBITDA of $61 million and $8.5 million, respectively.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: xbc
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

1 day ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

1 day ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

1 day ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

2 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago